Daewoong Biologics

Daewoong Biologics, specifically operating as Daewoong Biologics Indonesia (DBI), is a specialized biotechnology subsidiary of the South Korean healthcare leader Daewoong Pharmaceutical. Established in 2021, the company focuses on the development and manufacturing of advanced regenerative medicines, including stem cell and immune cell therapies. It operates a state-of-the-art, GMP-certified facility in Cikarang, Indonesia, which is capable of producing allogeneic and autologous mesenchymal stem cells, natural killer (NK) cells, and cell-free products such as secretomes and exosomes. Daewoong Biologics serves as a strategic hub for the group's expansion into Southeast Asia, providing high-quality biopharmaceuticals and cosmeceuticals while collaborating with local academic and medical institutions to advance personalized medicine.